Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
TAK
Takeda Pharmaceutical Company Limited
Takeda is a large-cap pharmaceutical company with a diversified, high-revenue drug portfolio and pipeline.
|
$55.67B |
$17.82
+0.25%
|
|
AME
AMETEK, Inc.
Paragon Medical alignment indicates AMETEK provides Medical Device Components as part of its Electromechanical Group.
|
$54.39B |
$236.33
+2.65%
|
|
ZTS
Zoetis Inc.
Zoetis markets vaccines for companion animals and livestock, a major revenue and product category.
|
$53.93B |
$122.38
+2.81%
|
|
ARGX
argenx SE
argenx's core offerings are monoclonal antibody therapeutics, including VYVGART.
|
$51.82B |
$849.68
+2.57%
|
|
MET
MetLife, Inc.
Health Insurance is offered as part of Group Benefits/employee benefits.
|
$51.45B |
$78.10
+1.31%
|
|
CAH
Cardinal Health, Inc.
Nuclear medicine radiopharmaceuticals distribution and related imaging agents.
|
$50.84B |
$214.00
+0.42%
|
|
IDXX
IDEXX Laboratories, Inc.
IDEXX manufactures in-clinic diagnostic instruments and related software (e.g., VetLab analyzers, Catalyst) and provides point-of-care diagnostics.
|
$47.05B |
$589.76
+3.48%
|
|
EW
Edwards Lifesciences Corporation
Core product category including SAPIEN/TAVR, Pascal, Evoque, and SAPIEN M3 used in structural heart interventions.
|
$46.97B |
$80.94
+2.38%
|
|
BDX
Becton, Dickinson and Company
BD is a global medical devices & biometrics company with multiple device-based offerings and biometric sensing capabilities.
|
$45.25B |
$158.53
+2.40%
|
|
BBD
Banco Bradesco S.A.
Health insurance products within Bradesco's Insurance Group.
|
$44.50B |
$4.21
+1.57%
|
|
HLN
Haleon plc
Panadol and other analgesics position Haleon in OTC Pain Relief & Analgesics.
|
$44.28B |
$9.74
+1.62%
|
|
PUK
Prudential plc
Health insurance offerings are a central pillar of Prudential's business strategy and geographic footprint.
|
$41.06B |
$30.89
+1.26%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
Alnylam's core product modality is RNA interference (RNAi) therapeutics, including approved products AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
|
$40.91B |
$309.87
-3.20%
|
|
VTR
Ventas, Inc.
Healthcare Services & Facilities captures ownership/operation of healthcare facilities including senior housing and outpatient spaces.
|
$39.97B |
$85.09
-0.49%
|
|
ALC
Alcon Inc.
Alcon directly designs and manufactures ophthalmology devices including intraocular lenses and surgical platforms.
|
$39.94B |
$81.33
+2.24%
|
|
SLF
Sun Life Financial Inc.
Health insurance offerings (including group health solutions and stop-loss) are key to Sun Life's business.
|
$39.24B |
$70.27
+2.42%
|
|
ROP
Roper Technologies, Inc.
Verathon bronchoscopes and other medical devices place Roper squarely in Medical Devices & Biometrics.
|
$39.01B |
$362.42
+0.15%
|
|
ONC
BeOne Medicines Ltd.
Core oncology-focused biotech; primary business segment is oncology therapeutics.
|
$35.87B |
$323.52
+0.88%
|
|
A
Agilent Technologies, Inc.
Agilent provides diagnostic instrument platforms used in life sciences and clinical diagnostics.
|
$34.55B |
$121.86
+3.05%
|
|
SHG
Shinhan Financial Group Co., Ltd.
Health insurance is a significant component of SHG's insurance offerings.
|
$34.44B |
$69.04
+2.55%
|
|
GEHC
GE HealthCare Technologies Inc.
GE HealthCare's core product portfolio centers on medical imaging devices and imaging systems (CT/MR/PET).
|
$34.01B |
$74.64
+1.97%
|
|
JBL
Jabil Inc.
Aseptic filling and dry oral dosage capabilities via Pharmaceutics International (Pii) reflect contract manufacturing services in pharma.
|
$33.97B |
$321.61
+3.71%
|
|
KVUE
Kenvue Inc.
Kenvue directly manufactures and sells OTC analgesics (e.g., Tylenol).
|
$33.74B |
$17.61
+0.86%
|
|
RMD
ResMed Inc.
CPAP devices and masks are core ResMed medical devices.
|
$33.30B |
$228.07
+1.49%
|
|
PAYX
Paychex, Inc.
Health Insurance; PEO insurance solutions for employees.
|
$33.01B |
$91.95
-0.19%
|
|
INSM
Insmed Incorporated
Brensocatib is an oral small molecule therapeutic targeting DPP1, a core part of Insmed's pipeline.
|
$30.81B |
$144.51
+1.20%
|
|
IQV
IQVIA Holdings Inc.
IQVIA operates as outsourced drug development and clinical research services akin to a CRO.
|
$30.00B |
$176.43
+2.60%
|
|
NTRA
Natera, Inc.
Natera's Signatera MRD and Signatera Genome tests are liquid biopsy assays using cfDNA to detect minimal residual disease in cancer, a core liquid biopsy product.
|
$28.76B |
$208.48
+6.31%
|
|
RVMD
Revolution Medicines, Inc.
Clinical-stage biotech focused on oncology; primary products are RAS(ON) inhibitors for cancer.
|
$28.73B |
$148.53
-0.50%
|
Showing page 3 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
